OBJECTIVE: Examine maternal and infant medical outcomes of prenatal exposure to methamphetamine (MA). STUDY DESIGN: Four hundred and twelve mother-infant pairs (204 MA-exposed and 208 unexposed matched comparisons) were enrolled in the Infant Development, Environment and Lifestyle (IDEAL) study. Exposure was determined by maternal self-report during this pregnancy and/or positive meconium toxicology. Maternal interviews assessed prenatal drug use, pregnancy course, and sociodemographic information. Medical chart reviews provided medical history, obstetric complications, infant outcomes, and discharge placement. RESULTS: MA-using mothers were more likely to be poor, to have a psychiatric disorder/emotional illness and less prenatal care, and to be less likely to breast-feed their infant than comparison mothers. After adjusting for covariates, MA-exposed infants were more likely to exhibit poor suck, to have smaller head circumferences and length, to require neonatal intensive care unit (NICU) admission, and to be referred to child protective services (CPS). Several outcomes previously reported from studies that lacked adequate control groups or adjustment for covariates were not significantly different in this study. CONCLUSION: Prenatal MA exposure is associated with maternal psychiatric disorder/emotional illness, poor suck, NICU admission, and CPS involvement, and MA-exposed infants were less likely to be breast-fed; however, the absence of many serious complications, such as fetal distress, chronic hypertension, preeclampsia, placenta previa, abruptio placentae, and cardiac defects, suggests confounding variables influenced prior studies. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
OBJECTIVE: Examine maternal and infant medical outcomes of prenatal exposure to methamphetamine (MA). STUDY DESIGN: Four hundred and twelve mother-infant pairs (204 MA-exposed and 208 unexposed matched comparisons) were enrolled in the Infant Development, Environment and Lifestyle (IDEAL) study. Exposure was determined by maternal self-report during this pregnancy and/or positive meconium toxicology. Maternal interviews assessed prenatal drug use, pregnancy course, and sociodemographic information. Medical chart reviews provided medical history, obstetric complications, infant outcomes, and discharge placement. RESULTS: MA-using mothers were more likely to be poor, to have a psychiatric disorder/emotional illness and less prenatal care, and to be less likely to breast-feed their infant than comparison mothers. After adjusting for covariates, MA-exposed infants were more likely to exhibit poor suck, to have smaller head circumferences and length, to require neonatal intensive care unit (NICU) admission, and to be referred to child protective services (CPS). Several outcomes previously reported from studies that lacked adequate control groups or adjustment for covariates were not significantly different in this study. CONCLUSION: Prenatal MA exposure is associated with maternal psychiatric disorder/emotional illness, poor suck, NICU admission, and CPS involvement, and MA-exposed infants were less likely to be breast-fed; however, the absence of many serious complications, such as fetal distress, chronic hypertension, preeclampsia, placenta previa, abruptio placentae, and cardiac defects, suggests confounding variables influenced prior studies. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: Lynne Smith; M Lynn Yonekura; Toni Wallace; Nancy Berman; Jennifer Kuo; Carol Berkowitz Journal: J Dev Behav Pediatr Date: 2003-02 Impact factor: 2.225
Authors: Sabrina D Diaz; Lynne M Smith; Linda L LaGasse; Chris Derauf; Elana Newman; Rizwan Shah; Amelia Arria; Marilyn A Huestis; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: J Pediatr Date: 2014-03-12 Impact factor: 4.406
Authors: Fleur L Warton; Ernesta M Meintjes; Christopher M R Warton; Christopher D Molteno; Nadine M Lindinger; R Colin Carter; Lilla Zöllei; Pia Wintermark; Joseph L Jacobson; Andre van der Kouwe; Sandra W Jacobson Journal: Neurotoxicol Teratol Date: 2017-10-22 Impact factor: 3.763
Authors: Lynne M Smith; Sabrina Diaz; Linda L LaGasse; Trecia Wouldes; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester Journal: Neurotoxicol Teratol Date: 2015-07-23 Impact factor: 3.763
Authors: Linda Chang; Kenichi Oishi; Jon Skranes; Steven Buchthal; Eric Cunningham; Robyn Yamakawa; Sara Hayama; Caroline S Jiang; Daniel Alicata; Antonette Hernandez; Christine Cloak; Tricia Wright; Thomas Ernst Journal: JAMA Psychiatry Date: 2016-12-01 Impact factor: 21.596